These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16175139)

  • 41. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
    Luo W; Yu H; Zou X; Ni X; Wei J
    Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
    Bao Y; Zhao J; Li ZZ
    Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
    Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of cladribine and fludarabine on DNA methylation in K562 cells.
    Wyczechowska D; Fabianowska-Majewska K
    Biochem Pharmacol; 2003 Jan; 65(2):219-25. PubMed ID: 12504797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
    Citores MJ; Castejon R; Villarreal M; Rosado S; Garcia-Marco JA; Vargas JA
    Exp Hematol; 2010 Mar; 38(3):165-73. PubMed ID: 20026377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Estey E; Plunkett W; Gandhi V; Rios MB; Kantarjian H; Keating MJ
    Leuk Lymphoma; 1993 Mar; 9(4-5):343-50. PubMed ID: 8394169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
    Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
    Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells.
    Michelutti A; Michieli M; Damiani D; Melli C; Ermacora A; Grimaz S; Candoni A; Russo D; Fanin R; Baccarani M
    Haematologica; 1997; 82(2):143-7. PubMed ID: 9175315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
    Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
    Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V; Robertson LE; Keating MJ; Plunkett W
    Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
    Lachmann N; Czarnecki K; Brennig S; Phaltane R; Heise M; Heinz N; Kempf H; Dilloo D; Kaever V; Schambach A; Heuser M; Moritz T
    Leukemia; 2015 Nov; 29(11):2266-9. PubMed ID: 25921248
    [No Abstract]   [Full Text] [Related]  

  • 53. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
    Loughlin S; Gandhi V; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1996; 38(3):261-8. PubMed ID: 8646801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
    Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
    Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
    Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A
    Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E; Jamy O; Martin MG
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
    Goto S; Goto H; Yokosuka T
    Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
    Jensen K; Johnson LA; Jacobson PA; Kachler S; Kirstein MN; Lamba J; Klotz KN
    Naunyn Schmiedebergs Arch Pharmacol; 2012 May; 385(5):519-25. PubMed ID: 22249336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
    Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.